Literature DB >> 17096350

Whole genome tiling path array CGH analysis of segmental copy number alterations in cervical cancer cell lines.

William W Lockwood1, Bradley P Coe, Ariane C Williams, Calum MacAulay, Wan L Lam.   

Abstract

Cervical cancer is the second most common malignancy in women worldwide, with high risk subtypes of human papillomavirus (HPV) constituting the major etiological agent. However, only a small percentage of women infected by the virus develop disease, suggesting that additional host genetic alterations are necessary for disease progression. In this study we examined the genomes of a panel of commonly used model cervical cancer cell lines using a recently developed whole genome tiling path array for CGH analysis. Detailed analysis of genomic profiles enabled the detection of many novel aberrations, which may have been missed by conventional cytogenetic methods. In total, 27 minimal regions of recurrent copy number alteration were identified that are potentially involved in tumorigenesis. Interestingly, fine mapping of the 3q gain, which is associated with the progression of precursor lesions to invasive cervical cancer, identified a minimal region of alteration harboring genes distinct from previous candidates. Novel regions of gene amplification, including the coamplification of both the Birc and MMP gene clusters on 11q22, were also evident. Lastly, characterization of genomic structure at sites of HPV integration identified the copy number gain of host cellular sequences between the viral-host genomic boundaries in both SiHa and SW756, suggesting a direct role for HPV integration in the development of genetic abnormalities that initiate cervical cancer. This work represents the highest resolution look at a cervical cancer genome to date and offers definitive characterization of the alteration status of these cancer cell lines. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17096350     DOI: 10.1002/ijc.22335

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  BIRC2 amplification in squamous cell carcinomas of the uterine cervix.

Authors:  M Choschzick; A M Tabibzada; F Gieseking; L Woelber; F Jaenicke; G Sauter; R Simon
Journal:  Virchows Arch       Date:  2012-06-26       Impact factor: 4.064

2.  The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells.

Authors:  Fei Yan; Na Shen; Jiuxia Pang; Julian R Molina; Ping Yang; Shujun Liu
Journal:  J Biol Chem       Date:  2015-06-17       Impact factor: 5.157

3.  Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Authors:  J Rafael Sierra; Virna Cepero; Silvia Giordano
Journal:  Mol Cancer       Date:  2010-04-12       Impact factor: 27.401

4.  An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer.

Authors:  Raj Chari; Bradley P Coe; Emily A Vucic; William W Lockwood; Wan L Lam
Journal:  BMC Syst Biol       Date:  2010-05-17

5.  Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma.

Authors:  William W Lockwood; Raj Chari; Bradley P Coe; Kelsie L Thu; Cathie Garnis; Chad A Malloff; Jennifer Campbell; Ariane C Williams; Dorothy Hwang; Chang-Qi Zhu; Timon P H Buys; John Yee; John C English; Calum Macaulay; Ming-Sound Tsao; Adi F Gazdar; John D Minna; Stephen Lam; Wan L Lam
Journal:  PLoS Med       Date:  2010-07-27       Impact factor: 11.069

6.  Oncogenic function of SCCRO5/DCUN1D5 requires its Neddylation E3 activity and nuclear localization.

Authors:  Claire C Bommeljé; Víola B Weeda; Guochang Huang; Kushyup Shah; Sarina Bains; Elizabeth Buss; Manish Shaha; Mithat Gönen; Ronald Ghossein; Suresh Y Ramanathan; Bhuvanesh Singh
Journal:  Clin Cancer Res       Date:  2013-11-05       Impact factor: 12.531

7.  MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.

Authors:  Takafumi Kubo; Hiromasa Yamamoto; William W Lockwood; Ilse Valencia; Junichi Soh; Michael Peyton; Masaru Jida; Hiroki Otani; Tetsuya Fujii; Mamoru Ouchida; Nagio Takigawa; Katsuyuki Kiura; Kenji Shimizu; Hiroshi Date; John D Minna; Marileila Varella-Garcia; Wan L Lam; Adi F Gazdar; Shinichi Toyooka
Journal:  Int J Cancer       Date:  2009-04-15       Impact factor: 7.396

8.  DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers.

Authors:  W W Lockwood; R Chari; B P Coe; L Girard; C Macaulay; S Lam; A F Gazdar; J D Minna; W L Lam
Journal:  Oncogene       Date:  2008-04-07       Impact factor: 9.867

9.  PIK3CA mutations and copy number gains in human lung cancers.

Authors:  Hiromasa Yamamoto; Hisayuki Shigematsu; Masaharu Nomura; William W Lockwood; Mitsuo Sato; Naoki Okumura; Junichi Soh; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Hiroshi Date; Wan L Lam; John D Minna; Adi F Gazdar
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

10.  Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung.

Authors:  Ji Un Kang; Sun Hoe Koo; Kye Chul Kwon; Jong Woo Park; Jin Man Kim
Journal:  BMC Cancer       Date:  2009-07-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.